Agrin induces both phosphorylation and aggregation of nicotinic acetylcholine receptors (AChRs) when added to myotubes in culture, apparently by binding to a specific receptor on the myotube surface. One such agrin receptor is alpha-dystroglycan, although binding to alpha-dystroglycan appears not to mediate AChR aggregation. To determine whether agrin-induced AChR phosphorylation is mediated by alpha-dystroglycan or by a different agrin receptor, fragments of recombinant agrin that differ in affinity for alpha-dystroglycan were examined for their ability to induce AChR phosphorylation and aggregation in mouse C2 myotubes. The carboxy-terminal 95 kDa agrin fragment agrin-c95(A0B0), which binds to alpha-dystroglycan with high affinity, failed to induce AChR phosphorylation and aggregation. In contrast, agrin-c95(A4B8) which binds less strongly to alpha-dystroglycan, induced both phosphorylation and aggregation, as did a small 21 kDa fragment of agrin, agrin-c21(B8), that completely lacks the binding domain for alpha-dystroglycan. We conclude that agrin-induced AChR phosphorylation and aggregation are triggered by an agrin receptor that is distinct from alpha-dystroglycan.
Introduction
An important step in the formation of the vertebrate skeletal neuromuscular junction is the nerve-induced accumulation of nicotinic acetylcholine receptors (AChRs), acetylcholinesterase (AChE) and other components, in the post-synaptic apparatus. Agrin, a protein originally isolated from Torpedo electric organ, appears to play a crucial role in this process (McMahan and Wallace, 1989; McMahan, 1990; Hall and Sanes, 1993) . Agrin is synthesized by motor neurons, is transported anterogradely along their axons and is deposited in the synaptic basal lamina. When added to myotubes in culture, agrin induces the formation of specializations at which many components of the postsynaptic apparatus accumulate, including AChRs and AChE. Both nerve-and agrin-induced AChR aggregation are blocked by anti-agrin antibodies (Reist et al., 1992) . These and other findings suggest that agrin is the neural signal that triggers the formation of post-synaptic specializations at developing neuromuscular junctions.
Agrin is a 400-600 kDa heparan sulfate proteoglycan with a multi-domain structure Tsen et al., 1995) . Agrin's AChR-aggregating activity is localized to the 95 kDa carboxy-terminal portion of the protein, which contains three domains homologous to the globular (G) domains of the laminin X chain (Nitkin et al., 1987; Sasaki et al., 1988; Tsim et al., 1992; Ferns et al., 1993; Gesemann et al., 1995) . Various isoforms of agrin result as a consequence of alternative splicing within this region. Inserts at two sites near the carboxy-terminal end, designated as A and B in chick and ray and y and z in rat, appear to regulate the ability of agrin to induce AChR aggregation (Rupp et al., 1991 Ferns et al., , 1993 Ruegg et al., 1992; Smith et al., 1992) . Each of the splice sites lies within or adjacent to a G-domain. For the A site, the presence or absence of a four amino acid insert results in A4 and AO variants, whereas for the B site there are 0, 8 and/or 11 amino acids inserted leading to BO, B8, B 11 and B 19 isoforms (see Figure 1) . In chick and rat, agrin isoforms that contain amino acid inserts at the B site always have the four amino acid insert at the A site. Recombinant carboxy-terminal fragments of agrin isoforms with inserts at both splice sites, such as A4B8, A4B 11 and A4B 19 are capable of inducing AChR aggregation on cultured muscle cells. Motor neurons express high levels of such isoforms Hoch et al., 1993; Ma et al., 1994 Ma et al., , 1995 Smith and O'Dowd, 1994) . Muscle cells, on the other hand, synthesize agrin isoforms that lack inserts at one or both sites [AOBO, A4BO (Ruegg et al., 1992; Hoch et al., 1993; Ma et al., 1994) ]; such isoforms are only weakly active or inactive in AChR aggregation assays when added in a soluble form to cultured myotubes Gesemann et al., 1995) .
Previous work suggested that agrin-and nerve-induced AChR aggregation is mediated by an increase in protein tyrosine phosphorylation (Wallace et al., 1991; Qu and Huganir, 1994; Meier et al., 1995) . Thus, treatment of cultured myotubes with agrin leads to the formation of domains within myotubes that stain intensely with antibodies to phosphotyrosine (Wallace et al., 1991; Meier et al., 1995) . Agrin-induced AChR aggregates co-localize with such phosphotyrosine-enriched domains. Protein kinase antagonists that inhibit agrin-induced tyrosine phosphorylation also block agrin-induced AChR aggregation (Wallace, 1994) . One component of the myotube membrane that becomes phosphorylated on tyrosine residues in agrin-treated myotubes is the AChR itself, most conspicuously the AChR 0 subunit (Wallace et al., 1991; Qu and (Meier et al., 1995; Wallace, 1995) . A crucial step in testing such a hypothesis is the identification of the agrin receptor. Motivated by the observation that binding of laminin to a-dystroglycan is mediated by G-domains for which homologs exist in agrin, several laboratories have shown that agrin binds to a-dystroglycan, a component of the dystrophin-associated glycoprotein complex (for reviews, see Matsumura and Campbell, 1994; Tinsley et al., 1994) . This observation led to the hypothesis that binding of agrin to a-dystroglycan triggers the formation of AChR aggregates (Bowe et al., 1994; Campanelli et al., 1994; Gee et al., 1994; Sugiyama et al., 1994) . However some experimental results appear inconsistent with this hypothesis: (i) Agrin isoforms that are inactive in AChR aggregation assays bind to a-dystroglycan with an affinity that is similar to or higher than that of isoforms with AChR-aggregating activity (Sugiyama et al., 1994; Gesemann et al., 1996) . (ii) Excess amounts of the inactive agrin isoform c95AoBo do not block agrin-induced AChR aggregation, but cause only a slight shift in the dose-response curve (Gesemann et al., 1996) . (iii) Experiments using mAb 11H6, which blocks binding of agrin to a-dystroglycan, give conflicting results.
While Gee et al. (1994) reported that mAb IIH6 inhibited agrin-induced AChR aggregation, Sugiyama et al. (1994) and Cohen et al. (1995) saw little or no effect on agrinor nerve-induced receptor aggregation. Campanelli et al. (1994) found that mAb IIH6 influenced the size but not the number of agrin-induced receptor patches. (iv) Recent studies using recombinant agrin show that a 21 kDa fragment, comprising the B splice site with the eight amino acid insert and the most carboxy-terminal G-domain (c2l B8, see Figure 1 ), does not bind to a-dystroglycan but is sufficient to induce AChR aggregation on cultured myotubes (Gesemann et al.. , 1996 . This led to the conclusion that binding to ax-dystroglycan is not required for agrin-induced AChR aggregation (Gesemann et al., , 1996 . Here we report that in mouse C2 myotubes the ability of different agrin fragments and isoforms to induce AChR phosphorylation varied in parallel with their ability to induce AChR aggregation rather than with their ability to bind to a-dystroglycan. Isoforms that lack inserts at the A and B splice sites and bind with high affinity to a-dystroglycan caused neither AChR phosphorylation nor aggregation, while the small c21B8 fragment, which does not bind to a-dystroglycan, induced both AChR phosphorylation and aggregation. These findings support the hypothesis that the functional agrin receptor triggers both phosphorylation and aggregation and is distinct from a-dystroglycan.
Results
Agrin induces aggregation of AChRs on vertebrate skeletal myotubes and causes phosphorylation of the AChR , subunit. Agrin also binds to a-dystroglycan, although such binding does not appear to mediate AChR aggregation (Gesemann et al., 1996) . As a step towards identifying the agrin receptor mediating AChR phosphorylation, we have compared directly and quantitatively the ability of agrin fragments that differ in their affinity for adystroglycan to induce AChR aggregation and phosphorylation.
Binding to ac-dystroglycan is not sufficient for induction of AChR phosphorylation To study changes in the phosphorylation of AChR f8 subunits, cultured C2 myotubes were incubated overnight with medium containing [32P]orthophosphate and treated for 4 h with various isoforms of agrin. AChRs were purified, the subunits separated by SDS-PAGE and the incorporation of radioactive phosphate measured by autoradiography. As illustrated in Figure 2 , 85 pM of the recombinant agrin isoform c95A4B8, which is known to induce receptor aggregation, increased phosphorylation of the AChR 1 subunit to the same extent as was observed with saturating amounts of Torpedo agrin (Meier et al., 1995) . In contrast, 85 pM c95AOBo, an agrin isoform that is inactive in AChR aggregation assays but, like c95A4B8, binds to ax-dystroglycan (Sugiyama et al., 1994; Gesemann et al., 1996) , did not increase AChR P subunit phosphorylation over control levels. Likewise, laminin-1, another ligand for a-dystroglycan (Gee et al., 1994; Yamada et al., 1994; Gesemann et al., 1996) did not induce ,B subunit phosphorylation, at concentrations as high as 200 nM (data not shown). Thus, binding of agrin or laminin-1 to a-dystroglycan is not sufficient for the induction of phosphorylation of the AChR 1 subunit.
As demonstrated previously, Torpedo agrin not only induces AChR ,B subunit phosphorylation but also causes phosphorylation of AChR y and 6 subunits (Meier et al., 1995) . A comparable increase in AChR y and 6 subunit subunits were identified according to their Mr as described (Meier et al., 1995) . phosphorylation was observed with c9SA4B8, but not with c9SAoBo (data not shown). Phosphorylation of AChR y and 6 subunits occurs predominantly on serine residues, with little change in phosphotyrosine content (Meier et al., 1995) . Agrin-induced protein serine phosphorylation of the y and 6 subunits is not required for AChR aggregation (Wallace et al., 1991) ; therefore, we restricted our analyses to changes of AChR ,B subunit phosphorylation. inactive . These isoforms had the same relative potency on mouse C2 cells ( Figure 3A) . The concentration of c95A4B8 that induced half-maximal receptor aggregation was -100 pM, while c95A4BlI had a half-maximal response at -4 nM and c95AOBO failed to induce aggregation at concentrations as high as 200 nM. When assayed for their ability to induce phosphorylation of the AChR subunit ( Figure 3B ), these isoforms again had the same order of potency; c95A4B8 reached a halfmaximal response at -4 pM, c95A4B 1 at -50 pM and c95AoBO had no effect at concentrations as high as 200 nM.
The finding that the ability of different agrin isoforms to induce AChR phosphorylation varied in parallel with their AChR-aggregating activity is consistent with the hypothesis that the same agrin receptor mediates both effects.
A 21 kDa agrin fragment that lacks the binding domain for a-dystroglycan is sufficient to induce AChR aggregation and phosphorylation As previously shown, a short -21 kDa agrin fragment, comprising the third G-domain (G3) and the B splice site (c2lB8, see Figure 1 ), induces AChR aggregation on chick myotubes . To determine whether the third G-domain is sufficient to induce AChR phosphorylation and whether this effect is splice site dependent, we compared the ability of c21 Bo and c21B8 agrin fragments to induce AChR aggregation and subunit phosphorylation. Additionally, since agrin-induced AChR aggregation is inhibited by heparin (Wallace, 1990) and the second G-domain (G2) contains the heparin binding site (Gesemann et al., 1996) As shown in Figure 4 , the second G-domain was inactive in AChR aggregation and phosphorylation assays, regardless of the presence or absence of amino acid inserts at the A splice site. In contrast, the fragment containing the third G-domain induced both aggregation and phosphorylation, provided it contained an insert at the B splice site (c2lB8). The c2lBM fragment does not bind to ca-dystroglycan (Gesemann et al., 1996) . Thus, an agrin fragment that does not bind to a-dystroglycan induces both AChR phosphorylation and aggregation.
Next we compared the dose-response relationship for the formation of AChR aggregates and induction of c subunit phosphorylation for c2lB8 ( Figure 5 ). Halfmaximal receptor aggregation was reached at -4 nM, whereas half-maximal 0 subunit phosphorylation occurred at~300 pM. Thus, as was the case for c95 constructs, half-maximal phosphorylation occurred at a lower concentration of agrin than half-maximal receptor aggregation (see Discussion). AChR , subunits (Wallace et al., 1991; Qu and Huganir, 1994; Meier et al., 1995) and that protein tyrosine phosphorylation is required for agrin-induced AChR aggregation (Wallace, 1994 (Wallace, , 1995 
Discussion
The results reported here demonstrate that, when added to C2 myotubes in culture, the c21B8 fragment of recombinant agrin, which does not bind to a-dystroglycan, causes AChR aggregation and tyrosine phosphorylation of the AChR c subunit. On the other hand, the c95AoBo fragment of recombinant agrin, which binds with high affinity to a-dystroglycan, does not induce either AChR aggregation or phosphorylation. We conclude that agrin-induced AChR phosphorylation and aggregation are triggered by a muscle surface agrin receptor that is distinct from ax-dystroglycan.
Role of a-dystroglycan in mediating the effects of agrin The changes in AChR distribution and phosphorylation induced by the agrin fragment c21B8, which does not bind to a-dystroglycan, are qualitatively indistinguishable from those induced by longer agrin fragments, such as c95A4B8, that do bind to ax-dystrogylcan. This indicates that binding of agrin to ax-dystroglycan is not required for AChR phosphorylation or aggregation. However, a-dystroglycan does accumulate at agrin-and nerve-induced specializations and may well play a role in their formation and/or stabilization (Phillips et al., 1993; Campanelli et al., 1994; Cohen et al., 1995) . For example, Sugiyama et al. (1994) suggested that binding of agrin to a-dystroglycan might act to increase the effective concentration of agrin in the vicinity of developing aggregates, thereby facilitating its interaction with the agrin receptor that mediates AChR phosphorylation and aggregation. Indeed, Gesemann et al. (1996) provide evidence that binding to a-dystroglycan reduces the concentration of agrin required for a halfmaximal response by a factor of 2. Alternatively, a-dystroglycan, as well as other components of the dystrophin-utrophin complex, might be required for the interaction of AChRs with the cytoskeleton that is thought to mediate the immobilization of AChRs at sites of aggregate formation (Froehner, 1993; Cohen et al., 1995) . Thus, agrin-induced increases in protein tyrosine phosphorylation might alter the interactions between AChRs, the 43 kDa receptorassociated protein (rapsyn; Froehner, 1993) and proteins of the dystrophin-utrophin complex such that all of these components become tethered together to the underlying cytoskeleton. In fact, recent experiments using mutant mice with a targeted disruption of the Rapsn gene directly demonstrated the importance of rapsyn for the formation of AChR aggregates (Gautam et al., 1995) . On the other hand, interaction of agrin with a-dystroglycan might play a role unrelated to AChR aggregation, both at synaptic sites and elsewhere. In muscle for example, myofibers synthesize agrin isoforms, lacking inserts at one or both A and B splice sites, that bind to a-dystroglycan but do not induce AChR aggregation. a-Dystroglycan, in turn, is found in extrasynaptic regions of muscle fibers (Cohen et al., 1995 Agrin-induced AChR aggregation and phosphorylation Recombinant agrin fragments that induced AChR aggregation also caused AChR phosphorylation, while fragments that did not induce aggregation did not cause receptor phosphorylation. In particular, we found that the small recombinant chick agrin fragment c21B8 induced both tyrosine phosphorylation of the AChR P subunit and AChR aggregation. Thus, based on the constructs described in this report, the domains within agrin that mediate AChR aggregation could not be separated from those that cause phosphorylation; the third G-domain containing an insert at the B splice site is both necessary and sufficient to induce AChR phosphorylation and aggregation. These findings provide support for the hypothesis that the same agrin receptor triggers both AChR phosphorylation and aggregation.
Dose dependence of agrin-induced AChR aggregation and phosphorylation In previous experiments on chick myotubes, AChR aggregation and tyrosine phosphorylation were found to depend in the same manner on agrin concentration (Wallace, 1992) , as would be expected if the combination of agrin with a receptor on the myotube surface triggered an increase in tyrosine phosphorylation that caused AChR aggregation. In the current study on C2 myotubes, however, agrin-induced AChR phosphorylation reached halfmaximal levels at a concentration of agrin that was at least 10-fold lower than that necessary to induce halfmaximal AChR aggregation. The apparent discrepancy may result from the manner in which AChR aggregation was measured. In the present study, the extent of receptor aggregation was determined by estimating the fraction of the C2 cell surface covered by receptor aggregates. For this analysis, small aggregates (<4 gm in their longest axis) were ignored, and the density of receptors within aggregates was not taken into account. Thus, relatively small, low density aggregates, such as might be produced by low concentrations of agrin, would not contribute to the measured extent of aggregation, artifactually shifting the dose-response curve for aggregation to higher agrin concentrations.
Of course, other explanations cannot be ruled out. If aggregation were a cooperative process, requiring the interaction of several phosphorylated receptors for example, this would also tend to create a difference in the dose-response curves for aggregation and phosphorylation. Another possibility might be that proteins other than AChRs must become phosphorylated to a certain level before aggregation can occur.
Regardless of the relationship between AChR phosphorylation and aggregate formation, the results reported here demonstrate that both agrin-induced AChR phosphorylation and aggregation are mediated by a receptor that is distinct from a-dystroglycan.
Materials and methods

Agrin constructs and expression
The recombinant chick agnrin fragments used in this study were described by Gesemann et al. (1996) . Fragments comprising the second G-domain with or without the four amino acid insert at the A splice site are T. Meier et al. designated as G2A4 and G2AO respectively, whereas fragments composed of the third G-domain and the associated B splice site are designated c2IBo and c21B8 (Gesemann et al., , 1996 . Partially purified agrin from Torpedo electric organ (Cibacron pool) was prepared as described earlier (Nitkin et al., 1987) and used at a saturating dose (4 U).
Cell cultures and aggregation assays C2C12 cells (Yaffe and Saxel, 1977; Blau et al., 1983) were grown in 35 mm tissue culture dishes in proliferation medium until they reached confluence. Cells subsequently were changed to differentiation medium as described earlier Meier et al., 1995) . After 4-6 days, cells had fused and were used for AChR aggregation and phosphorylation assays. For aggregation assays, cultures were incubated with agrin isoforms for 16 h. AChRs were labeled with 4x 10-8 M rhodamine-a-bungarotoxin (Molecular Probes, Eugene, OR) and AChR aggregation was determined by estimating the fraction of the C2 cell surface covered by receptor aggregates. Only AChR aggregates with a longer axis of at least 4 jim were included in the counting (see Gesemann et al., 1995 for details).
Measurement of AChR phosphorylation
AChR phosphorylation was assayed as previously described (Meier et al., 1995) (Wallace et al., 1991; Meier et al., 1995) and toxinAChR complexes were solubilized by incubation for 10 min on ice in extraction buffer [20 mM sodium phosphate buffer, pH 7.4, supplemented with 5 mM EDTA, 5 mM EGTA, 50 mM sodium fluoride, 40 mM sodium pyrophosphate, 10 mM sodium molybdate, I mM sodium orthovanadate, 5 jg/mI aprotinin, 5 gg/ml leupeptin, 1 mM phenylmethylsulfonyl fluoride (PMSF), 1% (w/v) Triton X-100 and 0.25% (w/v) deoxycholate]. Extracts were cleared and toxin-AChR complexes purified on streptavidin-conjugated agarose beads. Bead complexes were washed thoroughly and eluted into SDS sample buffer at room temperature. AChR subunits were separated by SDS-PAGE on 7.5% gels. Gels were fixed, dried and exposed to pre-flashed autoradiography film (Hyperfilm-MP, Amersham, Arlington Heights, IL) and autoradiograms analyzed by densitometry as previously described (Wallace, 1994) . AChR j, and 6 subunits were identified by their position relative to pre-stained molecular weight markers and by criteria described previously (Meier et al., 1995) . For all densitometric analyses, data from different experiments were combined by normalizing the results of each experiment to the 6 subunit of control myotubes in normal medium (= 1000).
Assay for tyrosine phosphorylation
To estimate the level of tyrosine phosphorylation of AChR i subunits, isolated subunits were treated with base. Briefly, 32P-labeled AChR j3 subunits were identified on SDS-polyacrylamide gels, gel pieces cut out and total 32p incorporation determined by measuring Cerenkov radiation. Gel slices were treated with I M KOH at 60°C for 90 min to hydrolyze
[32p]PO4 from serine residues, washed and counted again. Alkali hydrolysis reduced the amount of radioactive phosphate in AChR f subunits isolated from control cultures by 76% (SEM: ± 2.8; N = 7), for c95A4B8-treated subunits by 55% (SEM: + 3.0; N = 7) and for c2IB8-treated subunits by 52% (SEM: ± 8.8; N = 6). The AChR J3 subunit contains phosphotyrosine and phosphoserine, but no detectable phosphothreonine (Qu and Huganir, 1994; Meier et al., 1995) . Since base treatment hydrolyzes >90% of phosphoserine residues while -40% of phosphotyrosine residues attached to proteins are recovered, we conclude that the radioactivity still associated with base-treated ,Bsubunits is due predominantly to phosphotyrosine (Cooper and Hunter, 1981) . Similar results were obtained using anti-phosphotyrosine antibodies on Western blots (data not shown).
